Peripheral Opioid Receptors in the Gut Can Independently Slow Digestion | Research

The takeaway

Gut opioid receptors can independently slow transit — and a peptide blocker reversed constipation without affecting brain-based pain relief.

Constipation separable from analgesia
Using a peripheral-only opioid antagonist

What the researchers found

Peripheral mu-opioid receptors in the gut can independently slow gastrointestinal transit. The peptide agonist PL017 slowed gut transit at 0.37 mg/kg but did not produce pain relief until 30 mg/kg, about 80 times higher. This proves gut mu receptors work independently of brain receptors.

Delta and kappa opioid receptors in the gut also slowed transit, but less powerfully than mu receptors.

The key finding: a peptide opioid antagonist that cannot cross the blood-brain barrier blocked morphine's gut-slowing effect without reducing its painkilling activity. This pharmacological separation means constipation and pain relief work through different receptor populations (gut vs brain).

Why it matters

Constipation is the most common side effect of opioid painkillers. This study proved constipation is caused by gut receptors, not brain receptors. This finding led directly to the development of peripheral opioid antagonists like methylnaltrexone (Relistor), which is now FDA-approved to treat opioid-induced constipation without reducing pain relief.

How the study worked

Mice received subcutaneous opioid agonists selective for mu, delta, and kappa receptors. Gastrointestinal transit was measured by tracking a charcoal meal through the gut. Pain was measured using the hot-plate test. Brain-impermeant peptide antagonists were given to separate central from peripheral effects. Multiple receptor types and routes of administration were tested.

What this study cannot tell us

Tested in mice, not people. The blood-brain barrier permeability of peptide antagonists may differ between mice and humans. Only acute dosing was studied. Chronic opioid use may change the peripheral/central balance.

How to read the evidence

Moderate animal study with clear pharmacological separation of peripheral vs central opioid effects.

When this study was published

Published in 1987 — this concept led to development of approved peripheral opioid antagonists like methylnaltrexone.

The bigger picture

Opioid-induced constipation affects millions of pain patients. This study showed it can be blocked peripherally without losing pain relief — the concept behind drugs like methylnaltrexone (Relistor).

Questions still open

Could peripheral opioid antagonists be combined with all opioid pain medications?
Are there other peripheral opioid side effects that can be similarly separated?

Common questions

Why do opioids cause constipation?

Opioid receptors in the gut wall slow muscle contractions and fluid secretion. This is separate from the brain-based pain relief — the gut has its own opioid receptor system.

Are there drugs that fix this?

Yes — methylnaltrexone (Relistor) and similar drugs block opioid receptors only in the gut, relieving constipation without reducing pain control. This study helped establish the concept.

Read the original research

Peptide opioid antagonist separates peripheral and central opioid antitransit effects.

The Journal of pharmacology and experimental therapeutics, 243(2), 492-500

View on PubMed ↗

Citation

Shook, J E; Pelton, J T; Hruby, V J; Burks, T F. (1987). Peptide opioid antagonist separates peripheral and central opioid antitransit effects.. The Journal of pharmacology and experimental therapeutics, 243(2), 492-500.